Skip to main content
    P

    Pluri Inc. (PLUR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    -0.01 (-0.95%)

    Market Cap: $15.09M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Pluri Inc. (PLUR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Pluri are Celularity (CELU), Collplant Biotechnologies (CLGN) and Quoin Pharmaceuticals Ltd DRC (QNRX). By market cap, Pluri ranks 6th of the 13 companies on this page; Estrella Immunopharma (ESLA) is the largest at $22.36M.

    Peer Comparison

    PLUR's revenue growth of -15.8% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Pluri (PLUR)$15.09MN/A8.7x0.0%-650.8%-15.8%0.00%
    Celularity Inc (CELU)$20.45MN/A1.0x-245.7%N/A-5.3%0.00%
    Collplant Biotechnologies Ltd (CLGN)$14.27MN/A21.0x0.0%N/A-39.7%0.00%
    Quoin Pharmaceuticals Ltd DRC (QNRX)$17.78MN/AN/A0.0%N/A0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Seres Therapeutics Inc (MCRB)$14.27MN/A6.6x0.0%N/A68.9%0.00%
    Biovie Inc (BIVI)$12.12MN/AN/A0.0%N/A0.0%0.00%
    Quantum BioPharma Ltd. (QNTM)$10.35MN/AN/A0.0%-150.1%0.0%0.00%
    Estrella Immunopharma Inc. (ESLA)$22.36MN/AN/A0.0%N/A0.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Akari Therapeutics PLC (AKTX)$15.54MN/AN/A0.0%N/A0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Psyence Biomedical Ltd. Common Shares (PBM)$12.00MN/AN/A0.0%N/A0.0%0.00%
    Peer median$14.39MN/A14.5x0.0%-111.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Pluri, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Celularity Inc (CELU)
    Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta.
    CELU competitors
    Collplant Biotechnologies Ltd (CLGN)
    CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs...
    CLGN competitors
    Quoin Pharmaceuticals Ltd DRC (QNRX)
    Quoin Pharmaceuticals Ltd (QNRX) is an innovative biotechnology firm dedicated to developing cutting-edge therapeutics for rare diseases...
    QNRX competitors
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    Seres Therapeutics Inc (MCRB)
    Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally...
    MCRB competitors
    Biovie Inc (BIVI)
    BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States.
    BIVI competitors
    Quantum BioPharma Ltd. (QNTM)
    Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases.
    QNTM competitors
    Estrella Immunopharma Inc. (ESLA)
    Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
    ESLA competitors
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    Akari Therapeutics PLC (AKTX)
    Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory...
    AKTX competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Psyence Biomedical Ltd. Common Shares (PBM)
    Psyence Biomedical Ltd. (PBM) is an innovative biotechnology company focused on harnessing the therapeutic potential of psychedelic compounds to address mental...

    Frequently Asked Questions About PLUR

    Who are Pluri's main competitors?

    The companies most similar to Pluri include Celularity (CELU), Collplant Biotechnologies (CLGN), Quoin Pharmaceuticals Ltd DRC (QNRX), Marker Therapeutics (MRKR) and Seres Therapeutics (MCRB), listed from the closest match.

    Who is Pluri's biggest competitor?

    Estrella Immunopharma (ESLA) is the largest of the similar companies at $22.36M; Celularity (CELU) is the closest match by business profile, size, sector and industry.

    How does PLUR stock compare with its competitors?

    PLUR's P/S is 8.7x against a peer median of 14.5x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Pluri's competitors pays a higher dividend?

    Pluri pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Pluri bigger than its competitors?

    No. Pluri is 6th by market cap among the 13 companies on this page; the largest is Estrella Immunopharma (ESLA) at $22.36M.